Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022

Rhea-AI Summary

Caladrius Biosciences, Inc. (Nasdaq: CLBS) announced its participation in several upcoming industry events, including the Biotech Showcase and H.C. Wainwright BioConnect Conference, both scheduled for January 2022 and held virtually. Presentations will be led by David J. Mazzo, PhD, President and CEO, and will be available on-demand. The company focuses on developing innovative therapies to treat diseases, with product candidates like XOWNA (CLBS16) for coronary microvascular dysfunction and CLBS12 for Buerger's Disease.

BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms.

• Biotech Showcase (January 10–12, 2022 and January 17–19, 2022)
  Location: Virtual
  Presenter: David J. Mazzo, PhD, President and CEO
  
  The Biotech Showcase will feature insights from top investors and biopharma executives. For more information on the conference and how to register, please visit https://informaconnect.com/biotech-showcase/.

• H.C. Wainwright BioConnect Conference (January 10-13, 2022)
  Location: Virtual
  Presenter: David J. Mazzo, PhD, President and CEO
  
  For more information on the conference and how to register, please contact your H.C. Wainwright representative directly or visit https://hcwevents.com/bioconnect/.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: XOWNA^® (CLBS16), the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA^® in Japan), recipient of  orphan designation for Buerger’s Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of CLI and Buerger’s Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for DKD. For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com

FAQ

What is Caladrius Biosciences participating in January 2022?

Caladrius Biosciences will participate in the Biotech Showcase and H.C. Wainwright BioConnect Conference, both held virtually.

Who will present at the upcoming Caladrius events?

David J. Mazzo, PhD, President and CEO of Caladrius Biosciences, will present at the events.

What product candidates does Caladrius Biosciences focus on?

Caladrius focuses on innovative therapies like XOWNA (CLBS16) for coronary microvascular dysfunction and CLBS12 for Buerger's Disease.

When is the Biotech Showcase event?

The Biotech Showcase is scheduled for January 10–12, 2022, and January 17–19, 2022.

What is the significance of XOWNA (CLBS16)?

XOWNA (CLBS16) is a promising product candidate that recently completed a positive Phase 2a study and has initiated a Phase 2b study.